Citryll B.V.;
Citryll B.V.
J Vis Exp. 2024 Oct 18(212). doi: 10.3791/67258.
Neutrophils play an important role in innate immune defense by using several strategies, including the release of neutrophil extracellular traps (NETs) in a process referred to as NETosis. However, in the past two decades, it has become clear that the accumulation of NETs in tissues contributes to the pathophysiology of multiple inflammatory and autoimmune diseases. Therefore, interest in the development of NETosis antagonists has risen. Variable and non-standardized methods to detect and analyze NETosis were developed concomitantly, each with its own advantages and limitations. Here, we describe a real-time microscopy method for the quantification of human NET release, allowing to study NETosis as well as NET inhibition in a high-throughput manner. The surface area-based semi-automated analysis recognizes NETs and distinguishes them from non-netting activated neutrophils. We demonstrate that the non-physiological NETosis inducers, calcium ionophore and phorbol-12-myristate-13-acetate (PMA), trigger the release of NETs with different characteristics and kinetics. Furthermore, we show that this approach allows studying NET release in response to disease-relevant stimuli, including immune complexes, N-Formylmethionine-leucyl-phenylalanine (fMLF), monosodium urate crystals, and calcium pyrophosphate crystals. To exemplify the utility of this method to study NETosis antagonists, we used CIT-013, a first-in-class monoclonal antibody inhibitor of NET release. CIT-013 targets citrullinated histone H2A and H4 and efficiently inhibits NET release with an IC50 of 4.6 nM. Other anti-histone antibodies tested lacked this NETosis-inhibitory capacity. Altogether, we demonstrate that this protocol enables specific, reliable, and reproducible high-throughput quantification of NETs, enhancing the study of NET release characteristics, kinetics, and pharmacology of NETosis antagonists.
中性粒细胞通过多种策略在先天免疫防御中发挥重要作用,包括释放被称为 NETosis 的中性粒细胞细胞外陷阱 (NETs)。然而,在过去的二十年中,人们清楚地认识到组织中 NETs 的积累导致了多种炎症和自身免疫性疾病的病理生理学。因此,人们对开发 NETosis 拮抗剂的兴趣日益增加。同时开发了可变的和非标准化的方法来检测和分析 NETosis,每种方法都有其自身的优点和局限性。在这里,我们描述了一种用于定量检测人 NET 释放的实时显微镜方法,该方法允许以高通量方式研究 NETosis 以及 NET 抑制。基于表面积的半自动分析可识别 NETs 并将其与未发生 NETosis 的活化中性粒细胞区分开来。我们证明,非生理 NETosis 诱导剂,钙离子载体和佛波醇-12-肉豆蔻酸-13-乙酸酯 (PMA),以不同的特征和动力学触发 NET 的释放。此外,我们表明,这种方法允许研究对疾病相关刺激的 NET 释放,包括免疫复合物、N-甲酰基甲硫氨酸亮氨酸苯丙氨酸 (fMLF)、单钠尿酸盐晶体和焦磷酸钙晶体。为了举例说明该方法在研究 NETosis 拮抗剂中的应用,我们使用了 CIT-013,这是一种用于 NET 释放的首创单克隆抗体抑制剂。CIT-013 靶向瓜氨酸化组蛋白 H2A 和 H4,并以 4.6 nM 的 IC50 有效抑制 NET 释放。测试的其他抗组蛋白抗体缺乏这种 NETosis 抑制能力。总之,我们证明该方案能够特异性、可靠地和可重复地高通量定量 NETs,增强了对 NET 释放特征、动力学和 NETosis 拮抗剂药理学的研究。